Finance entity
All 1 tracked stories fall under one category: ipo. Tandem Diabetes Care is most often covered alongside Dexcom, which appears in 1 of these 1 story. The 6 average consequence score is below the beat benchmark of 6.3 in the same window.
Last mentioned: Mar 6, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: ipo. Tandem Diabetes Care is most often covered alongside Dexcom, which appears in 1 of these 1 story. The 6 average consequence score is below the beat benchmark of 6.3 in the same window. Each story carries 2 original sources on average, compared with 2.4 for the broader beat in this window. We currently track 1 Finance story that mention Tandem Diabetes Care, all published on March 6, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 95 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Tandem Diabetes Care. Shared-story counts are live from our verified record — not editorial picks.
Medtronic plc has priced the initial public offering of its diabetes-focused subsidiary, MiniMed Group Inc., at $20.00 per share for 28 million shares. The $560 million carve-out aims to provide the specialized unit with independent capital to compete in the high-growth insulin delivery and monitoring market.
Tandem Diabetes Care is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
